PEGBIO CO-B (02565) rose nearly 5% again. As of press time, it was up 3.57% at HK$3.335, with a turnover of HK$21.5625 million.
On the news front, the company's core product Paidakang® (Beinaglutide Injection) has been successfully included in the 2026 National Medical Insurance Drug Catalog, marking a major commercial milestone. Previously, PEGBIO entered into an exclusive commercialization partnership in mainland China with Shanghai Tengrui Pharmaceutical, setting a target of cumulative sales exceeding RMB 10 billion, with product sales revenue to be recognized by PEGBIO.
Public information shows that Paidakang is a once-weekly GLP-1 formulation used for blood glucose control in adults with type 2 diabetes. The company stated that Paidakang is the group's first approved innovative drug product, and its inclusion in the National Medical Insurance Catalog is expected to improve patient affordability and medication accessibility, which will help drive product admission, clinical promotion, and market coverage across medical institutions nationwide.
Comments